|
KMID : 1141320200350020125
|
|
Kosin Medical Journal
2020 Volume.35 No. 2 p.125 ~ p.132
|
|
|
Efficacy of Evolocumab in Patients with Hypercholesterolemia
|
|
Jin Xuan
Kim Moo-Hyun
Cho Young-Rak
Park Jong-Sung
Song Kai
Yuan Song Lin
|
|
|
Abstract
|
|
|
Objectives: The FOURIER trial reported that inhibition of PCSK9 with evolocumab on a background of statin therapy lowered low-density lipoprotein (LDL) cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. Here, we report data from a single center focusing on the effect of a PCSK9 inhibitor antibody on hyperlipidemia.
Methods: We enrolled 29 hypercholesterolemia patients who had LDL cholesterol levels ≥ 70 mg per deciliter or nonHDL cholesterol ≥ 100 mg per deciliter and were divided into two groups (placebo n = 14, evolocumab n = 15), and participated in a 72 - 96 week, randomized, double-blind, placebo-controlled trial with statin therapy. Patients were randomly assigned to receive evolocumab (140 mg every 2 weeks or 420 mg monthly) or matched placebo via subcutaneous injection. Lipid changes during follow-up were analyzed.
Results: The median LDL cholesterol level at baseline was 88 mg per deciliter, and the average LDL cholesterol level was 101.8 ± 20.0 mg per deciliter. At 4 weeks, the median LDL cholesterol level was 39 mg per deciliter, and the average LDL cholesterol level was 34.8 ± 51.8 mg per deciliter. Compared to placebo group, the LDL cholesterol levels were significantly reduced after treatment (P < 0.001), as well as total cholesterol, ApoB, and ApoB / ApoA1 levels. During follow-up, no discomfort was reported at local injection sites, and no cases of abnormal liver function were observed.
Conclusions: Evolocumab significantly reduced LDL cholesterol levels and was well tolerated.
|
|
|
KEYWORD
|
|
|
Cholesterol LDL, Hypercholesterolemia, Proprotein convertase, Subtilisin-kexin type 9
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|